Trial Outcomes & Findings for Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma (NCT NCT02490800)

Last Updated: 2024-06-26

Results Overview

First 28-day treatment cycle dose limiting toxicities (DLT) graded according to Common Terminology Criteria for Adverse Events (CTCAE) in the MTD-determining population in Phase 1 based on the number of participants with adverse effects as measure of tolerability at various dose levels

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

72 participants

Primary outcome timeframe

During first 28 day cycle

Results posted on

2024-06-26

Participant Flow

In the Phase 1 study, a total of 29 screening-failures occurred. Thus a total of 72 patients with advanced solid tumors, recurrent or progressive glioblastoma (GBM) or high-grade glioma (HGG) were enrolled in this Phase 1 and Phase 2a study.

Participant milestones

Participant milestones
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 2 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 4 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day The recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Overall Study STARTED	3	3	3	7	7	3	4	3	7	3	8	3	18
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	3	3	7	7	3	4	3	7	3	8	3	18

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 2 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 4 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day The recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Overall Study Adverse Event	0	0	0	2	3	2	0	0	0	0	0	2	2
Overall Study Withdrawal by Subject	0	0	0	1	0	0	0	0	1	0	0	0	0
Overall Study Progressive disease	3	3	3	4	4	1	4	3	6	2	7	1	10
Overall Study Patient enrolled in post-trial access	0	0	0	0	0	0	0	0	0	1	1	0	6

Baseline Characteristics

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 2 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 4 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily	Total n=72 Participants Total of all reporting groups
Age, Continuous	51.3 years STANDARD_DEVIATION 21.94 • n=5 Participants	66.7 years STANDARD_DEVIATION 10.50 • n=7 Participants	63.3 years STANDARD_DEVIATION 6.51 • n=5 Participants	61.0 years STANDARD_DEVIATION 16.55 • n=4 Participants	64.4 years STANDARD_DEVIATION 7.00 • n=21 Participants	65.7 years STANDARD_DEVIATION 12.06 • n=10 Participants	53.8 years STANDARD_DEVIATION 9.95 • n=115 Participants	53.7 years STANDARD_DEVIATION 7.77 • n=6 Participants	42.3 years STANDARD_DEVIATION 9.62 • n=6 Participants	45.3 years STANDARD_DEVIATION 11.50 • n=64 Participants	53.6 years STANDARD_DEVIATION 9.78 • n=17 Participants	51.3 years STANDARD_DEVIATION 16.74 • n=21 Participants	55.6 years STANDARD_DEVIATION 10.43 • n=22 Participants	55.7 years STANDARD_DEVIATION 12.52 • n=8 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	5 Participants n=4 Participants	6 Participants n=21 Participants	0 Participants n=10 Participants	2 Participants n=115 Participants	2 Participants n=6 Participants	3 Participants n=6 Participants	2 Participants n=64 Participants	2 Participants n=17 Participants	1 Participants n=21 Participants	3 Participants n=22 Participants	31 Participants n=8 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=10 Participants	2 Participants n=115 Participants	1 Participants n=6 Participants	4 Participants n=6 Participants	1 Participants n=64 Participants	6 Participants n=17 Participants	2 Participants n=21 Participants	15 Participants n=22 Participants	41 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	1 Participants n=17 Participants	1 Participants n=21 Participants	0 Participants n=22 Participants	2 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	1 Participants n=8 Participants
Race (NIH/OMB) White	3 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	7 Participants n=4 Participants	7 Participants n=21 Participants	3 Participants n=10 Participants	3 Participants n=115 Participants	3 Participants n=6 Participants	7 Participants n=6 Participants	3 Participants n=64 Participants	7 Participants n=17 Participants	2 Participants n=21 Participants	18 Participants n=22 Participants	69 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants

PRIMARY outcome

Timeframe: During first 28 day cycle

Population: MTD population: All patients from the safety set who met the following during the first 28-day treatment Cycle 1: * Received at least one dose of lisavanbulin and had experienced a DLT * Received at least 24 of the scheduled 28 doses for daily lisavanbulin administration, were not experiencing a DLT, had been observed for ≥ 28 days following the first dose, and had been evaluated for safety

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=23 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=24 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 1: Maximum Tolerated Dose (MTD) of Daily Oral Lisavanbulin	16 mg	30 mg	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Until the study discontinuation, on average 161 days (maximum of 381 days)

Population: The efficacy evaluable population (EEP) was the subset of the Full Analysis Population (FAP) who had at least one post baseline RANO assessment after having received at least 6 weeks of study treatment. For the primary endpoint, best objective response / objective response rate, the analysis was based on patients with measurable disease at baseline.

The best objective response was calculated as the proportion of patients responding (i.e., with a best observed objective response of complete or partial response) based on "radiological assessment in neuro-oncology (RANO)" criteria

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=9 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 2a: Best Objective Response Complete response	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Phase 2a: Best Objective Response Partial response	1 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Phase 2a: Best Objective Response Stable disease	4 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Phase 2a: Best Objective Response Progressive disease	4 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Until the study discontinuation, on average 161 days (maximum of 381 days)

Population: Number of patients in EEP with measurable disease at baseline

The ORR was calculated as the percentage of patients (rate) with complete and partial responses and its 95% Confidence Interval (CI) based on RANO criteria

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=9 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 2a: Objective Response Rate (ORR)	11.1 Percentage of participants Interval 0.3 to 48.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: TEAEs were defined as all events occurring after lisavanbulin treatment began and up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)

Population: Safety population: All patients who received at least one full or partial dose of lisavanbulin and had at least one post-baseline safety assessment

Number of patients experiencing treatment-emergent adverse events (TEAE) of CTCAE Grade 3 or 4

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Number of Patients With CTCAE Grade 3-4 TEAEs Number of patients with related TEAEs of Grade 3-4	0 Participants	0 Participants	1 Participants	2 Participants	4 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—	—	—
Number of Patients With CTCAE Grade 3-4 TEAEs Number of patients without TEAEs of Grade 3-4	3 Participants	2 Participants	2 Participants	2 Participants	2 Participants	1 Participants	3 Participants	3 Participants	6 Participants	2 Participants	4 Participants	2 Participants	10 Participants	—	—	—	—	—	—	—	—	—	—	—
Number of Patients With CTCAE Grade 3-4 TEAEs Number of patients with only unrelated TEAEs of Grade 3-4	0 Participants	1 Participants	0 Participants	3 Participants	1 Participants	0 Participants	1 Participants	0 Participants	1 Participants	1 Participants	4 Participants	0 Participants	5 Participants	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Plasma PK profiles were obtained on Cycle 1, Day 1 and on Cycle 2, Day 1 (pre-dose and from 0 up to 24 h post-dose) for all patients in the Phase 1 study who received lisavanbulin. For Phase 2 a study, PK parameters were obtained only on Cycle 1, Day 1

Population: The PK analysis set includes all patients who received at least one partial or complete dose of study drug (for the Phase 1 on Day 1 of Cycles 1 and 2, and for the Phase 2a only on Day 1 of Cycle 1) and had at least one post-baseline PK assessment

Pharmacokinetic parameter "Peak Plasma Concentration" Cmax of avanbulin Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862)

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=5 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=3 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=2 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=6 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=1 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Cmax of Avanbulin (BAL27862)	6.900 ng/mL Geometric Coefficient of Variation 0.580	9.800 ng/mL Geometric Coefficient of Variation 0.490	23.400 ng/mL Geometric Coefficient of Variation 0.440	40.880 ng/mL Geometric Coefficient of Variation 0.270	29.190 ng/mL Geometric Coefficient of Variation 0.490	44.270 ng/mL Geometric Coefficient of Variation 0.640	120.260 ng/mL Geometric Coefficient of Variation 0.490	109.560 ng/mL Geometric Coefficient of Variation 0.490	116.630 ng/mL Geometric Coefficient of Variation 0.580	147.730 ng/mL Geometric Coefficient of Variation 0.410	159.020 ng/mL Geometric Coefficient of Variation 0.080	35.260 ng/mL Geometric Coefficient of Variation 0.560	48.930 ng/mL Geometric Coefficient of Variation 0.910	75.130 ng/mL Geometric Coefficient of Variation 0.110	114.890 ng/mL Geometric Coefficient of Variation 0.430	64.110 ng/mL Geometric Coefficient of Variation 0.460	78.700 ng/mL Geometric Coefficient of Variation 0.640	103.950 ng/mL Geometric Coefficient of Variation 0.470	95.370 ng/mL Geometric Coefficient of Variation 0.110	146.500 ng/mL Geometric Coefficient of Variation 0.580	146.010 ng/mL Geometric Coefficient of Variation 0.340	159.100 ng/mL Geometric Coefficient of Variation 0.650	190.000 ng/mL Geometric Coefficient of Variation NA Not evaluable	98.210 ng/mL Geometric Coefficient of Variation 0.410

SECONDARY outcome

Pharmacokinetic parameter "Time to Peak Plasma Concentration" Tmax of avanbulin (BAL27862) Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862).

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=5 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=3 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=2 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=6 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=1 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Tmax of Avanbulin (BAL27862)	2.0 Hours Interval 1.1 to 3.0	1.2 Hours Interval 1.0 to 2.0	1.1 Hours Interval 1.0 to 2.0	1.1 Hours Interval 1.0 to 2.0	3.0 Hours Interval 1.0 to 4.1	2.0 Hours Interval 1.1 to 4.0	1.1 Hours Interval 1.0 to 2.2	1.2 Hours Interval 1.0 to 2.2	1.0 Hours Interval 1.0 to 2.1	1.1 Hours Interval 1.0 to 2.1	2.0 Hours Interval 1.1 to 3.0	1.5 Hours Interval 1.0 to 2.2	1.0 Hours Interval 1.0 to 1.1	1.1 Hours Interval 0.8 to 2.0	1.1 Hours Interval 1.0 to 2.1	1.2 Hours Interval 0.6 to 2.2	1.1 Hours Interval 1.0 to 2.1	1.0 Hours Interval 1.0 to 2.0	2.0 Hours Interval 2.0 to 2.0	2.0 Hours Interval 0.5 to 3.0	2.0 Hours Interval 1.0 to 2.2	2.2 Hours Interval 2.1 to 3.1	1.0 Hours Interval 1.0 to 1.0	2.0 Hours Interval 0.6 to 3.0

SECONDARY outcome

Pharmacokinetic parameter "Area under the plasma concentration versus time curve" AUC of avanbulin (BAL27862) Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862).

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=5 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=3 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=2 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=6 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=1 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 Participants RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
AUC of Avanbulin (BAL27862)	34.040 h*ng/mL Geometric Coefficient of Variation 0.840	74.020 h*ng/mL Geometric Coefficient of Variation 0.830	180.060 h*ng/mL Geometric Coefficient of Variation 0.150	356.490 h*ng/mL Geometric Coefficient of Variation 0.160	258.460 h*ng/mL Geometric Coefficient of Variation 0.320	439.660 h*ng/mL Geometric Coefficient of Variation 0.620	823.980 h*ng/mL Geometric Coefficient of Variation 0.350	896.420 h*ng/mL Geometric Coefficient of Variation 0.540	1014.130 h*ng/mL Geometric Coefficient of Variation 0.650	1265.130 h*ng/mL Geometric Coefficient of Variation 0.410	1649.350 h*ng/mL Geometric Coefficient of Variation 0.250	230.800 h*ng/mL Geometric Coefficient of Variation 0.800	331.800 h*ng/mL Geometric Coefficient of Variation 1.760	692.230 h*ng/mL Geometric Coefficient of Variation 0.160	814.930 h*ng/mL Geometric Coefficient of Variation 0.460	344.540 h*ng/mL Geometric Coefficient of Variation 0.580	507.360 h*ng/mL Geometric Coefficient of Variation 0.740	575.060 h*ng/mL Geometric Coefficient of Variation 0.440	790.340 h*ng/mL Geometric Coefficient of Variation 0.110	1055.130 h*ng/mL Geometric Coefficient of Variation 0.250	1296.470 h*ng/mL Geometric Coefficient of Variation 0.370	1264.610 h*ng/mL Geometric Coefficient of Variation 0.320	1146.110 h*ng/mL Geometric Coefficient of Variation NA Not evaluable	713.710 h*ng/mL Geometric Coefficient of Variation 0.480

SECONDARY outcome

Timeframe: Until the end of treatment, on average 151 days (maximum of 1653 days), every other 28 day cycle

Population: Full analysis population (FAP): All patients who received at least one partial or complete dose of study drug, based on the intent-to-treat (ITT) principle

The best objective response was calculated as the proportion of patients responding (i.e., with a best observed objective response of complete response (CR) or partial response (PR), according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 for patients with advanced or recurrent solid tumors); and based on RANO criteria for patients with recurrent or progressive GBM / HGG

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 1: Best Objective Response Complete response	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—
Phase 1: Best Objective Response Partial response	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—
Phase 1: Best Objective Response Stable disease	1 Participants	0 Participants	1 Participants	4 Participants	3 Participants	1 Participants	0 Participants	1 Participants	2 Participants	1 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—	—	—	—
Phase 1: Best Objective Response Progressive disease	2 Participants	3 Participants	2 Participants	2 Participants	4 Participants	2 Participants	4 Participants	2 Participants	5 Participants	1 Participants	5 Participants	1 Participants	—	—	—	—	—	—	—	—	—	—	—	—
Phase 1: Best Objective Response Missing	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Until the study discontinuation, on average 151 days (maximum 1653 days), every other 28 day cycle

Population: FAP (Phase 1 portion of the study)

The ORR was calculated as the percentage of patients (rate) with complete and partial responses and its 95% CI based on RECIST criteria v1.1 for patients with advanced or recurrent solid tumors; and based on RANO criteria for patients with recurrent or progressive GBM / HGG

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=4 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 1: Objective Response Rate (ORR)	0 Percentage of patients Interval 0.0 to 70.8	0 Percentage of patients Interval 0.0 to 70.8	0 Percentage of patients Interval 0.0 to 70.8	0 Percentage of patients Interval 0.0 to 41.0	0 Percentage of patients Interval 0.0 to 41.0	0 Percentage of patients Interval 0.0 to 70.8	0 Percentage of patients Interval 0.0 to 60.2	0 Percentage of patients Interval 0.0 to 70.8	0 Percentage of patients Interval 0.0 to 41.0	33.3 Percentage of patients Interval 0.8 to 90.6	12.5 Percentage of patients Interval 0.3 to 52.7	0 Percentage of patients Interval 0.0 to 70.8	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 1 year

Population: PFS was summarized for the FAP and EEP

PFS was defined as the interval between the date of drug administration and the earliest date of objective disease progression based on RANO criteria for patients with recurrent or progressive GBM / HGG. Patients who have not progressed or died at the end of the study were censored at the time of their latest objective tumor assessment.

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=18 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=13 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 2a: PFS	2.5 Months Interval 1.4 to 7.5	3.5 Months Interval 1.6 to Value(s) could not be evaluable due insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 6 months

Population: FAP and EEP

Percentage of patients without disease progression based on RANO criteria 6 months after the start of treatment. The values were determined using the Kaplan-Meier and Brookmeyer-Crowley methods.

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=18 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=13 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 2a: PFS at 6 Months	31.3 Percentage of participants Interval 11.8 to 53.1	43.3 Percentage of participants Interval 16.3 to 67.9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 1 year

Population: FAP and EEP

Percentage of patients alive 12 months after the start of treatment. The values were determined using the Kaplan-Meier and Brookmeyer-Crowley methods.

Outcome measures

Outcome measures
Measure	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin n=18 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 30 mg/day	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin n=13 Participants Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 8 to 35 mg/day	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 16 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Advanced or Recurrent Solid Tumors: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 1, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Cycle 2, Day 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Cycle 1, Day 1 Patients With Recurrent GBM: Lisavanbulin 25 mg/Day RP2D of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Phase 2a: Overall Survival (OS) at 12 Months	42.9 percentage of patients Interval 15.9 to 67.8	55.6 percentage of patients Interval 20.4 to 80.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Deaths: 0 deaths

Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day

Serious events: 8 serious events

Other events: 18 other events

Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure	Phase 1 Patients Solid Tumors: Lisavanbulin 2 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 4 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 8 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 16 mg/Day n=7 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 20 mg/Day n=7 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 30 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=4 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 participants at risk The recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily
Investigations Alanine aminotransferase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Aspartate aminotransferase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Troponin I increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Atrial fibrillation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Ataxia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Cognitive disorder	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Dysarthria	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Headache	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Ischaemic stroke	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Partial seizures	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Seizure	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Somnolence	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Thalamic infarction	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Aspiration	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Constipation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Haematemesis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Intestinal obstruction	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Nausea	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Vomiting	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Urinary incontinence	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Urinary retention	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Sepsis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Urinary tract infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Accidental overdose	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Fall	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Fractured coccyx	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Stoma prolapse	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cholangiocarcinoma	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intracranial tumour haemorrhage	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Disease progression	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Fatigue	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Gait disturbance	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders General physical health deterioration	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Peripheral swelling	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Pyrexia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Hepatobiliary disorders Cholangitis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Confusional state	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Delirium	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Hallucination	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Hallucination, visual	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)

Other adverse events

Other adverse events
Measure	Phase 1 Patients Solid Tumors: Lisavanbulin 2 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 4 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 8 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 16 mg/Day n=7 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 20 mg/Day n=7 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Solid Tumors: Lisavanbulin 30 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 8 mg/Day n=4 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 15 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 20 mg/Day n=7 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 25 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 30 mg/Day n=8 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 1 Patients With Recurrent or Progressive GBM / HGG: Lisavanbulin 35 mg/Day n=3 participants at risk Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily	Phase 2a Patients With Recurrent GBM: Lisavanbulin 25 mg/Day n=18 participants at risk The recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily
Investigations Blood alkaline phosphatase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Blood bilirubin increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Blood creatine phosphokinase decreased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Blood creatine phosphokinase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Blood creatinine increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Blood glucose increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Electrocardiogram abnormal	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Gamma-glutamyltransferase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Lipase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Lymphocyte count decreased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Neutrophil count decreased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Neutrophil count increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Troponin T increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Troponin increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Weight decreased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations White blood cell count decreased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations White blood cell count increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Alanine aminotransferase increased	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	37.5% 3/8 • Number of events 5 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	22.2% 4/18 • Number of events 5 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Investigations Aspartate aminotransferase increased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 2/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Myocardial ischaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Palpitations	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Sinus bradycardia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Sinus tachycardia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Tachycardia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Ventricular arrhythmia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Cardiac disorders Ventricular extrasystoles	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Blood and lymphatic system disorders Neutrophilia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Amnesia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Aphasia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Balance disorder	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Brain oedema	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Cognitive disorder	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Coordination abnormal	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Disturbance in attention	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Dizziness	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Dysarthria	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Facial paralysis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Headache	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Hemianopia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Hemiparesis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	22.2% 4/18 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Hyporesponsive to stimuli	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Lethargy	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Memory impairment	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Meralgia paraesthetica	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Migraine	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Neuralgia	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Neurologic neglect syndrome	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Neuropathy peripheral	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Paraesthesia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Partial seizures	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Peroneal nerve palsy	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Restless legs syndrome	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Sciatica	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Seizure	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 6 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 6 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Sensory loss	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Nervous system disorders Tremor	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 2/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Eye disorders Blepharitis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Eye disorders Cataract	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Eye disorders Cataract subcapsular	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Eye disorders Eye pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Eye disorders Visual impairment	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Eye disorders Vitreous floaters	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Ear and labyrinth disorders Ear pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Ear and labyrinth disorders Otorrhoea	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Ear and labyrinth disorders Tinnitus	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Ear and labyrinth disorders Vertigo	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Dyspnoea	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Epistaxis	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Abdominal discomfort	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Abdominal pain	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Abdominal pain lower	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Anal incontinence	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Constipation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Defaecation urgency	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Diarrhoea	33.3% 1/3 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 5 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Dry mouth	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Dysphagia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Epigastric discomfort	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Intestinal fistula	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Lip dry	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Mouth ulceration	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Nausea	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Oral pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Rectal perforation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Stomatitis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Gastrointestinal disorders Vomiting	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Bladder discomfort	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Calculus urinary	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Haematuria	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Micturition urgency	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Nephrolithiasis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Nocturia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Pollakiuria	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Polyuria	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Renal colic	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Renal and urinary disorders Urinary incontinence	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Cold sweat	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Hair colour changes	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Hair growth abnormal	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Pruritus	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Skin disorder	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Skin and subcutaneous tissue disorders Xeroderma	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Back pain	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Limb discomfort	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Musculoskeletal and connective tissue disorders Sacral pain	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Decreased appetite	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	28.6% 2/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 6 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Hypophagia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Vitamin B12 deficiency	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Metabolism and nutrition disorders Vitamin D deficiency	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations COVID-19	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	22.2% 4/18 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Candida infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Cystitis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Escherichia urinary tract infection	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Fungal infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Gastroenteritis viral	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Hordeolum	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Lip infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Lower respiratory tract infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Nasopharyngitis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Oral candidiasis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Oral herpes	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Rhinitis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Skin infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Upper respiratory tract infection	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Urinary tract infection	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Infections and infestations Viral infection	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Contusion	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Fall	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	75.0% 3/4 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Procedural pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Injury, poisoning and procedural complications Skin laceration	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Haemangioma of liver	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to meninges	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Vascular disorders Hot flush	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Vascular disorders Hypertension	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Vascular disorders Hypotension	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Chills	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Early satiety	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Fatigue	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	42.9% 3/7 • Number of events 4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	66.7% 2/3 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	44.4% 8/18 • Number of events 10 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Gait disturbance	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	16.7% 3/18 • Number of events 3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders General physical health deterioration	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Localised oedema	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Oedema peripheral	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Pyrexia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
General disorders Unevaluable event	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Hepatobiliary disorders Hepatic cyst	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Hepatobiliary disorders Hyperbilirubinaemia	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Reproductive system and breast disorders Acquired phimosis	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Reproductive system and breast disorders Erectile dysfunction	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Agitation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Anxiety	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Confusional state	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	11.1% 2/18 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Depressed mood	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Depression	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Disorientation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Hallucination	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Hallucination, visual	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Insomnia	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	14.3% 1/7 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 1/4 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	25.0% 2/8 • Number of events 2 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 1/3 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	33.3% 6/18 • Number of events 6 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Libido decreased	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	12.5% 1/8 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/18 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Psychomotor retardation	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)
Psychiatric disorders Somnambulism	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/4 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/7 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/8 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	0.00% 0/3 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)	5.6% 1/18 • Number of events 1 • Treatment-emergent events occurring after lisavanbulin treatment began, up to 28 days after last study drug administration which corresponded to a maximum of 1653 days (4,5 years)

Additional Information

Thomas Kaindl, MD

Basilea Pharmaceutica International Ltd, Allschwil

Phone: +41 61 567 15 24

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60